TTN as a candidate gene for distal arthrogryposis type 10 pathogenesis

Anik Biswas1†, Sudipta Deb Nath1†, Tamim Ahsan2, M. Monir Hossain3, Sharif Akhteruzzaman1 and Abu Ashfaqur Sajib1*

Abstract

Background: Arthrogryposis is a medical term used to describe congenital contractures which often affect multiple limbs. Distal arthrogryposis (DA) is one of the major categories of arthrogryposis that primarily affects the distal parts of the body, i.e., the hands and the legs. Although ten different types and several subtypes of DAs have been described, the genes associated with each of these DAs are yet to be characterized. Distal arthrogryposis type 10 (DA10) is a rare genetic disease, which is distinguished from the other arthrogryposis types by plantar flexion contractures resulting in toe-walking during infancy as well as variability in contractures of the hip, hamstring, elbow, wrist and finger joints with no ocular or neurological abnormalities. Symptoms of DA10 indicate impairment specifically in the musculoskeletal system. DA10 is still poorly studied.

Aim: The objective of this study was to identify the candidate gene for DA10 by scrutinizing the protein-protein interaction (PPI) networks using in silico tools.

Results: Among the genes that reside within the previously reported genomic coordinates (human chromosome assembly 38 or GRCh38 coordinates 2:179,700,000–188,500,000) of the causative agent of DA10, only TTN (the gene that codes for the protein Titin or TTN) follows the expression pattern similar to the other known DA associated genes and its expression is predominant in the skeletal and heart muscles. Titin also participates in biological pathways and processes relevant to arthrogryposes. TTN-related known skeletal muscle disorders follow the autosomal-dominant pattern of inheritance, which is a common characteristic of distal arthrogryposes as well.

Conclusion: Based on the findings of the analyses and their correlation with previous reports, TTN appears to be the candidate gene for DA10. Our attempt to discover a potential candidate gene may eventually lead to an understanding of disease mechanism and possible treatment strategies, as well as demonstrate the suitability of PPI in the search for candidate genes.

Keywords: Distal arthrogryposis, Congenital contractures, Protein-protein interaction network, Titin, TTN

Background

“Arthrogryposis” is derived from the Greek words “arthron”, meaning joint, and “gryposis” meaning curvature [1]. Arthrogryposis and arthrogryposes multiplex congenita (AMC) are used as generalized terms to describe inborn congenital contractures, which often affect multiple limbs [2]. These descriptive terms, however, do not denote any specific diagnosis for such conditions as AMCs have been recognized in different conditions [2, 3]. One child in every 3000 to 5100 live births is born with arthrogryposis with different levels of penetrance [1, 4]. Decreased in utero fetal movement is observed in every affected case, but the cause of such diminished movement can be vastly
different [2]. In addition to maternal effects such as a bicor- nuate uterus, oligohydramnios, or intrauterine crowding (observed in twins) [5], mutations in certain genes contribute to AMC development [6].

Bamshad et al. described the most widely accepted clinical classification of AMC. According to this classification, AMC can be caused by amyoplasia, neurological abnormalities, or distal arthrogryposis. Amyoplasia is caused by impaired muscle growth leading to contractures that affect every symmetrical joint of the body. Internally rotated shoulders, extended elbows, flexed wrists, dislocated hips, equinovarus contractures in the feet, rigid fingers, and thumbs are common symptoms in these cases [5]. Many patients also have a mid-facial hemangioma. Most of these patients, however, have normal intelligence. Hereditary components have not been established for AMC caused by amyoplasia, and surgical intervention is usually needed for treatment [1]. Complications during central nervous system development and peripheral neuropathies can also lead to decreased fetal movement and arthrogryposis [5]. Occasionally, auto-antibodies from the mother can target fetal acetylcholine receptors and cause neuropathies in the fetus [1]. AMCs are inherited in an autosomal recessive manner, whereas the types and sub-types of distal arthrogryposes (DAs) are mostly autosomal dominant in nature [1, 4, 5, 7–9]. DA primarily affects the distal parts of the body, i.e., the hands and the legs. It is the second largest cause of AMC after amyoplasia [10]. According to the classification proposed by Bamshad et al [5], DA is characterized by multiple congenital contractures without a primary muscular or neurological disorder. DA patients are usually treated with the goal of improving the motor function of affected joints, strengthening muscles with physiotherapies, and correcting deformities through surgery [11].

Ten different types and several subtypes of DAs have been characterized and classified according to their proportion of shared features [5]. However, the genes associated with each type of DAs are yet to be categorized. DA10 is distinguished from the AMCs and other DAs by plantar flexion contractures, resulting in toe-walking during infancy [12, 13]. Additionally, patients show variability in contractures of the hip, hamstring, elbow, wrist, and finger joints [13]. Like the other DAs, DA10 is still poorly studied. In this study, we scrutinized the interactions among the already known arthrogryposis-associated gene products through protein-protein interaction (PPI) network analyses as well as database search and explored the potential candidate gene associated with the development of distal arthrogryposis type 10 (DA10).

Methods
Identification of the interactors of arthrogryposis-associated proteins
The list of genes that are known to be associated with different types and subtypes of DA (Table 1) was retrieved from the Online Mendelian Inheritance in Man® (OMIM®) database [6]. These genes were used as input in NetworkAnalyst 3.0 [14] to identify their interactors through exploring the non-redundant set of physical molecular interaction data at the IMEx [15] and the STRING (with experimental evidence and high confidence score) databases [16]. Based on these protein-protein interaction networks, the associated pathways and processes were identified (with a false discovery rate or FDR <0.05) from the Gene Ontology (Biological Process) [17], PANTHER (Biological Process) [18], Reactome [19] and KEGG [20] databases and roles of different interactors in these pathways and processes were retrieved. Based on their roles, the interactors proteins that are relevant to arthrogryposis were identified and their chromosomal locations were collected from database resources at the National Center for Biotechnology Information (NCBI) [21].

Identification of functionally relevant genes associated with arthrogryposis
Based on genome-wide linkage analysis, a previous study reported that the candidate gene for DA10 resides on human chromosome 2 within the region between 179,700,000 and 188,500,000 bps in the chromosome assembly 38 (GRCh38) (equivalent to genomic coordinates 2:179,390,716–179,672,150 in the human chromosome assembly 37 or GRCh37) [12]. The list of genes that are located within these genomic coordinates on human chromosome 2 was retrieved from the Atlas of Genetics and Cytogenetics in Oncology and Haematology database [22]. In addition, the genes of the interactor proteins that are relevant to arthrogryposis (mentioned in the previous section), and reside within the previously suggested region [12] or very close to the defined region (as genetic linkage does not provide absolute distance in base pairs) were identified. Expression and functions of these gene-encoded proteins were explored in the Human Protein Atlas database [23] and genes functionally relevant to DA10 were identified.

Identification of potential candidate gene
The functionally relevant genes to DA10 (identified through PPI network analysis as well as the Atlas of Genetics and Cytogenetics in Oncology and Haematology database) were used as input in NetworkAnalyst 3.0 [14] to identify their roles in biological pathways and processes (FDR <0.05) based on the data at the STRING
database (with experimental evidence and high confidence score). Participation of these proteins in muscle contraction-related pathways was explored by identifying the pathways and processes (FDR <0.05) from the Gene Ontology (Biological Process), PANTHER (Biological Process), Reactome, and KEGG pathway databases, and their relevance to DA10 pathogenesis was scrutinized.

Results

Interactions among the known arthrogryposis-associated gene products

Mutations in different genes cause arthrogryposis (Table 1). Even mutations at different loci in certain genes are associated with several types of DAs (Table 1). While visualizing the interactions among the proteins encoded by the 15 arthrogryposes associated genes using the IMEx interactome database, a total of 151 nodes were found that incorporated 14 of the query genes as nodes (Fig. 1A). The biological pathways and processes (retrieved from the Gene Ontology, PANTHER, Reactome, and KEGG databases) associated with these 151 nodal proteins (Table 2) were similar.

The same query genes were used as input to search protein-protein interactions and associated biological processes in the STRING interactome database (Table 3). Among the five sub-networks obtained, only the largest sub-network showed relevance to AMCs and DAs. There was considerable overlap among the pathways and processes identified based on IMEx and STRING databases. The total number of distinct nodes (proteins) in these two PPI networks obtained through IMEx and STRING interactome databases summed up to 180. These genes and their corresponding number of interactions are shown in Supplementary Table 1.

Since the known genes that are associated with different types of distal arthrogryposis appeared to be connected through PPI, we hypothesized the presence of the candidate gene for DA10 to be within the network. Genome-wide linkage analysis of 5 generations of a family with DA10 has pointed to the cytogenetic location 2q31.3–q32.1 to be associated with DA10. This location corresponds to the GRCh38 genomic coordinates 2:179,700,000–188,500,000, and GRCh37 genomic coordinates 2:179,700,000–188,500,000 (Table 1) [6, 12]. Therefore, the member proteins of the PPI networks that reside on chromosome 2

| Arthrogryposis type | Associated gene | Mode of inheritance |
|---------------------|-----------------|---------------------|
| Arthrogryposis multiplex congenita 1 | LG4 | Autosomal recessive |
| Arthrogryposis multiplex congenita 2 | ERGIC1 | Autosomal recessive |
| Arthrogryposis multiplex congenita 3 | SYNE1 | Autosomal recessive |
| Arthrogryposis multiplex congenita 4 | SCYL2 | Autosomal recessive |
| Arthrogryposis multiplex congenita 5 | TOR1A | Autosomal recessive |
| Distal arthrogryposis, type 1A | TPM2 | Autosomal dominant |
| Distal arthrogryposis, type 1B | MYBPC1 | Autosomal dominant |
| Distal arthrogryposis, type 1C | MYLPF | Autosomal dominant |
| Distal arthrogryposis, type 2A (Freeman-Sheldon syndrome) | MYH3 | Autosomal dominant |
| Distal arthrogryposis, type 2B1 | TNNT2 | Autosomal dominant |
| Distal arthrogryposis, type 2B2 | TNNT3 | Autosomal dominant |
| Distal arthrogryposis, type 2B3 (Sheldon-Hall syndrome) | MYH3 | Autosomal dominant |
| Distal arthrogryposis, type 2B4 | TPM2 | Autosomal dominant |
| Distal arthrogryposis, type 3 | PIEZO2 | Autosomal dominant |
| Distal arthrogryposis, type 4 | Not Mapped | Autosomal dominant |
| Distal arthrogryposis, type 5 | PIEZO2 | Autosomal dominant |
| Distal arthrogryposis, type 5D | ECEL1 | Autosomal dominant |
| Distal arthrogryposis, type 6 | Not Mapped | Autosomal dominant |
| Distal arthrogryposis, type 7 (Trismus-pseudocamptodactyly syndrome) | MYH8 | Autosomal dominant |
| Distal arthrogryposis, type 8 (Contractures, pterygia, and spondylocarpotarsal fusion syndrome 1A) | MYH3 | Autosomal dominant |
| Distal arthrogryposis, type 9 | FBN2 | Autosomal dominant |
| Distal arthrogryposis, type 10 | Cytogenetic location: 2q31.3–q32.1 | Autosomal dominant |
| | Genomic coordinates (GRCh38): 2:179,700,000–188,500,000 | |
Fig. 1  PPI networks generated using 15 known genes associated with AMCs and DAs based on (A) IMEx and (B) STRING databases. AMC and DA-associated gene-encoded proteins are shown in red and the other interacting proteins are shown in green.
were identified. Among the 180 nodes (proteins), only 8 are encoded by genes that reside on human chromosome 2 (Table 4). Only one of these genes, *TTN*, appears to be very closely located to the predicted genomic coordinates of the DA10 candidate gene (Table 1).

We also looked for other potential candidate genes for DA10 by retrieving the list of genes that reside within 2q31.3–q32.1 (Table 5). Thirty-three genes reside within this region on human chromosome 2. Among the 12 PPI sub-networks identified using these genes as input in Metaboanalyst, only one sub-network comprising ITGAV, NCKAP1, and ITGA4 appeared to be involved in the regulation of actin cytoskeleton (with experimental evidence and high confidence score), which is relevant to arthrogryposis development [24] (Fig. 2).

Three among these genes (MIR4437, MIR548AE1, and MIR561) that reside within 2q31.3–q32.1 encode miRNAs. Target genes of these miRNAs were retrieved from the miRDB [25] with a cut-off for prediction score ≥95 (Supplementary Table 2). Experimental evidence for these miRNA targets that reside on chromosome 2 was retrieved from miRTarBase [26] (Supplementary Table 2). None of these target genes are located within the previously reported genomic coordinates of the causative agent of DA10.
The four potential candidate gene products—ITGA4, ITGAV, NCKAP1, and TTN, were used as inputs along with the other DA-associated genes in the STRING interactome database (with experimental evidence and high confidence score) to assess the most probable candidate gene for DA10. Input of TTN along with the 15 known AMCs and DAs associated genes generated a more extensive PPI network with 230 nodes (Fig. 3). ITGAV was found to be associated only with the FBN2 gene (associated with DA9) in the same network at this confidence level (Fig. 4). ITGA4 and NCKAP1 appeared to form isolated sub-networks (Fig. 4).

Discussion

In this study, we used in silico tools and databases to identify the candidate gene for distal arthrogryposis type 10. Our exploration suggests the involvement of Titin (TTN) in the development of DA10.

| Gene   | Chromosome | Genomic coordinates           |
|--------|------------|-------------------------------|
| CLIP4  | 2          | 29,097,681..29,183,808        |
| PKD3   | 2          | 37,250,502..37,324,833        |
| ATP6V1B | 2         | 70,935,900..70,965,431        |
| DYSF   | 2          | 71,453,154..71,686,763        |
| KBTBD10| 2          | 169,509,702..169,526,258      |
| TTN    | 2          | 178,525,989..178,807,423      |
| ECEL1  | 2          | 232,479,827..232,487,834      |
| PPP1R7 | 2          | 241,149,573..241,183,662      |

**Table 4** List and genomic coordinates of the genes in the PPI network that are positioned on human chromosome 2

**Table 5** List of the genes at 2q31.3–q32.1 on human chromosome 2

| Gene name | GRCh38 location | Cytogenetic location | Gene product                                             |
|-----------|-----------------|----------------------|----------------------------------------------------------|
| CWC22     | 179944.877      | 2q31.3               | CWC22 spliceosome-associated protein homolog             |
| SCHLAP1   | 180692.104      | 2q31.3               | SWI/SNF complex antagonist associated with prostate cancer 1 |
| UBE2E3    | 180980.385      | 2q31.3               | Ubiquitin-conjugating enzyme E2 E3                       |
| LINCO1934 | 181123.837      | 2q31.3               | Long intergenic non-protein coding RNA 1934              |
| MIR4437   | 181305.593      | 2q31.3               | MicroRNA 4437                                           |
| ITGA4     | 181456.892      | 2q31.3               | Integrin subunit alpha 4                                |
| CERKL     | 181536.674      | 2q31.3               | Ceramide kinase like                                     |
| NEUROD1   | 181676.106      | 2q31.3               | Neuronal differentiation 1                              |
| ITPR2     | 181891.730      | 2q31.3               | ITPR interacting domain containing 2                    |
| PPP1R1C   | 181905.853      | 2q31.3–q32.1         | Protein phosphatase 1 regulatory inhibitor subunit 1C     |
| PDE1A     | 182140.041      | 2q32.1               | Phosphodiesterase 1A                                    |
| DNAJC10   | 182716.257      | 2q32.1               | DnaJ heat shock protein family (Hsp40) member C10       |
| FRZB      | 182833.276      | 2q32.1               | Frizzled-related protein                                |
| NCKAP1    | 182909.115      | 2q32.1               | NCK-associated protein 1                                |
| DUSP19    | 183078.747      | 2q32.1               | Dual specificity phosphatase 19                         |
| NUP35     | 183124.355      | 2q32.1               | Nucleoporin 35                                           |
| MIR548AE1 | 184378.975      | 2q32.1               | MicroRNA 548ae-1                                        |
| ZNF804A   | 184598.366      | 2q32.1               | Zinc finger protein 804A                                 |
| LOC105373782| 185164.954  | 2q32.1               | Uncharacterized LOC105373782                            |
| FSIP2     | 185738.985      | 2q32.1               | Fibrous sheath interacting protein 2                     |
| FSIP2-AS1 | 185788.020      | 2q32.1               | FSIP2 antisense RNA 1                                    |
| LINCO1473 | 186033.534      | 2q32.1               | Long intergenic non-protein coding RNA 1473             |
| ZC3H15    | 186486.260      | 2q32.1               | Zinc finger CCCH-type containing 15                     |
| ITGAV     | 186590.056      | 2q32.1               | Integrin subunit alpha V                                |
| FAM171B   | 186694.060      | 2q32.1               | Family with sequence similarity 171 member B             |
| ZSWIM2    | 186827.480      | 2q32.1               | Zinc finger SWIM-type containing 2                      |
| CALCRL    | 187341.965      | 2q32.1               | Calcitonin receptor like receptor                        |
| TFPI      | 187464.231      | 2q32.1               | Tissue factor pathway inhibitor                          |
| LINCO1090 | 188035.596      | 2q32.1               | Long intergenic non-protein coding RNA 1090             |
| MIR561    | 188297.492      | 2q32.1               | MicroRNA 561                                            |
| GULP1     | 188291.874      | 2q32.1–q32.2         | GULP PTB domain containing engulfment adaptor 1         |
**TTN** is a large gene with 364 exons and multiple splice variants [27]. **TTN** is expressed in the striated muscles—cardiac and skeletal muscles [28]. Since **TTN** is not expressed in other tissues, non-muscular abnormalities are not supposed to occur in titinopathies. This is consistent with the results from a previous study on DA10 patients, which found all DA10 patients to have normal neurological responses, electromyographic patterns, and creatinine kinase levels [12]. The majority of the **TTN**-related skeletal muscle disorders follow the autosomal-dominant pattern of inheritance [27], which is a common characteristic of distal arthrogryposes as well [12].

The N2A isoform of **TTN** is predominantly present in the skeletal muscles, and this N2A isoform excludes some of the exons of predominant cardiac isoforms N2B and N2BA. That is why, mutations of **TTN** can result in isolated cardiomyopathies, isolated skeletal muscle disorders, and combined cardiac-skeletal muscle diseases [27].

Tibial muscular dystrophy (TMD) is caused by mutations in the **TTN** and manifests itself in the adult patient as weakening of the tibialis anterior muscle [27]. In Finnish TMD patients, FINmaj mutation (an 11-bp deletion) was found in the last exon of **TTN** [29]. TMD patients having pelvic and shoulder muscle disorders were found to carry homozygous FINmaj mutations [27]. Other frameshift and missense mutations in the **TTN** contributed to phenotypic severity among the TMD patients [30]. Similarly, DA10 patients also show variability in the number and severity of affected joints [12].

There are reports on the involvement of **TTN** in congenital contractures. Fernández-Marmiesse et al. have shown that a homozygous deletion of 5-bp in a prenatal exon of **TTN** (exon 197) causes a frameshift leading to a premature truncated protein, which results in congenital contractures [31]. Chervinsky et al. have shown another lethal contracture syndrome, where homozygous deletion is present in exon 167 of **TTN**, which is part of the fetal **TTN** isoform [32]. Bryen et al. have reported autosomal recessive form of arthrogryposis in patients having splice-site variant at intron 213 of **TTN** [33]. These observations clearly state that a wide range of mutations can change the characteristics of **TTN** for disease development, sometimes resulting in arthrogryposis. This is not uncommon, since different mutations in PIEZO2, TPM2, and MYH3 are known to cause different types of DAs.

The biological pathways and processes associated with these 151 nodal proteins (Table 2) are shared by different distal arthrogryposes. For example, patients with DA type 1 and its subtypes show mutations in genes TPM2, MYBPC1, and MYLPF that cause impairment of muscle

---

**Fig. 2** PPI sub-network that includes ITGAV, ITGA4, and NCKAP1
Fig. 3  PPI networks generated using the genes along with 15 known genes associated with AMCs and DAs based on (A) IMEx and (B) STRING interactome databases through NetworkAnalyst. AMC and DA-associated gene-encoded proteins along with TTN are shown in red and the other interacting proteins are shown in green.
contraction, and affect the binding of actin filament [34–36]. Patients with DA type 2 and DA type 7 have issues with muscle development because of mutations in the troponin and myosin proteins [37–40]. On the other hand, the most prominent pathways identified through the KEGG database included hypertrophic cardiomyopathy, dilated cardiomyopathy, cardiac muscle contraction, and adrenergic signaling in cardiomyocytes. Since no report has established links of hypertrophic cardiomyopathy, dilated cardiomyopathy, cardiac muscle contraction, and/or adrenergic signaling in cardiomyocytes with distal arthrogryposis, this calls for further exploration in DA patients. The genes associated with these pathways are shown in Supplementary Figure 1.

As shown in Tables 2 and 3, the nodes (proteins) in the PPI network (Fig. 1) participate in pathways like actin filament-based movement, muscle contraction, cytoskeleton organization, muscle organ development, cardiomyopathy, ITGA4, ITGAV, and NCKAP1, which are all found in the 2q31.3–q32.2 chromosomal region, where the candidate gene for DA10 is thought to lie, do not appear to be viable candidates for DA10 because they are not seen in skeletal or muscular disorders to any significant level [12]. NCKAP1 has been shown to be associated with cancer metastasis in non-small cell lung carcinoma [41], hepatocellular carcinoma [42], autism [43], and Alzheimer's disease [44]. ITGA4 is associated with multiple sclerosis [45], autism [46], and metastasis of cholangiocarcinoma [47], among others. ITGAV is associated in many conditions as melanoma [48], prostate cancer adhesion [49], and rheumatoid arthritis [50], etc.

Tissue-specific expression profiles also reveal similarities between TTN and other DA-associated genes [28]. Other than TPM2 and PIEZO2, gene expression profiles of all other candidate genes of different distal arthrogryposis are restricted to specific organs (Supplementary figure 2). TTN appears to share this characteristic with other DA-associated genes, as TTN is expressed only in the striated muscle tissues (Supplementary figure 2). As mentioned earlier, DA10 is distinguished from the AMCs and other DAs by plantar flexion contractures, resulting in toe-walking during infancy, in addition to variable contractures of the hip, hamstring, elbow, wrist, and finger joints [12, 13]. These symptoms indicate impairment in the musculoskeletal system. On the contrary, NCKAP1 and ITGAV have generalized expression patterns in

![Fig. 4 Interactions of ITGA4 (A), ITGAV (B) and NCKAP1 (C) with the known AMC and DA-associated proteins. Only the interactions with a high confidence score and experimental evidences are shown in the figure. AMC and DA-associated gene-encoded proteins along with ITGAV, ITGA4, and NCKAP1 are shown in red and the other interacting proteins are shown in green.](image-url)
different tissues, whereas ITGA4 expression is more restricted to cells of immune and lymphatic systems (Supplementary figure 3) [28]. NCKAPI, ITGAV, and ITGA4 do not show specificity or high expressivity at the muscular tissues.

There are several sources that linked DA10 with the F-box protein 8 (FBXO8) [51, 52]. However, the cytogenetic location of FBXO8 is 4q34.1 [6], which contradicts with the previously identified location of DA10 candidate gene at 2q31.3–q32.2 [12]. Additionally, FBXO8 shows a general‐ized expression pattern, with no expression in the skeletal, smooth, or heart muscle (Supplementary figure 4). FBXO8 protein also does not interact with the other DA-associated proteins in the PPI network. Considering these facts, we hypothesize TTN to be the candidate gene of DA10. Association of TTN with DA10 may be investigated further using targeted gene sequencing of DA10 patients. Knowledge about the genetic basis of DA10 may aid in understanding the pathogenesis mechanism as well as developing more effective therapeutic strategies in the future.

Conclusions
In this study, we scrutinized the protein-protein interaction (PPI) networks as well as the associated biological processes and pathways to identify the candidate gene for DA10. TTN resides within the previously reported genomic coordinates of the potential candidate gene of DA10. TTN is predominantly expressed in the skeletal and heart muscles and its expression follows a pattern similar to the other known DA-associated genes. TTN participates in biological pathways and processes relevant to arthrogryposis. Based on the findings of these in silico analyses and their correlation with previous reports, TTN appears to be the candidate gene for DA10.

Abbreviations
AMC: Arthrogryposis multiplex congenita; DA: Distal arthrogryposis; DA10: Distal arthrogryposis type 10; FDR: False discovery rate; PPI: Protein-protein interaction.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s43141-022-00405-5.

Additional file 1: Supplementary Table 1. List of interacting proteins in the network shown in Fig. 1.

Additional file 2: Supplementary Table 2. List of target genes of MIR4437, MIR548A1 and MIR561 encoded miRNAs.

Additional file 3: Supplementary Figure 1. The DA associated genes (in red) that participate in hypertrophic cardiomyopathy, dilated cardiomyopathy and/or adrenergic signaling in cardiomyocytes pathways. The other nodes that participate in these pathways are shown in blue. The rest of the interacting proteins are shown in green.

Additional file 4: Supplementary Figure 2. Tissue specific expression profiles of TTN and genes known to be associated with DAs [28].

Additional file 5: Supplementary Figure 3. Tissue specific expression profiles of ITGA4, ITGAV, and NCKAPI [28].

Additional file 6: Supplementary Figure 4. Tissue specific expression profiles of FBXO2 [28].

Acknowledgements
This study was supported by a grant under special allocation in science and technology from the Ministry of Science and Technology, Bangladesh to AAS. The authors are thankful for the support.

Authors’ contributions
AB: methodology, acquisition of data, and manuscript preparation. SDN: methodology, analysis of data, and manuscript preparation. TA: analysis and interpretation of data. MMH: interpretation and manuscript reviewing. SA: interpretation and manuscript reviewing. AAS: conceptualization, interpretation of data, and manuscript reviewing. The author(s) read and approved the final manuscript.

Funding
Ministry of Science and Technology, Bangladesh.

Availability of data and materials
All data generated or analyzed during this study are included in this published article (and its supplementary information files).

Declarations
Ethics approval and consent to participate
This study neither involved any human nor animal, and hence, no ethical approval was required.

Consent for publication
This study did not involve any human and personal data (any individual details, images, or videos), and hence no consent for publication was required.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Genetic Engineering & Biotechnology, University of Dhaka, Dhaka 1000, Bangladesh. 2Molecular Biotechnology Division, National Institute of Biotechnology, Savar, Dhaka 1349, Bangladesh. 3Department of Neonatal Medicine, Bangladesh Institute of Child Health, Dhaka 1207, Bangladesh.

Received: 19 January 2022 Accepted: 4 July 2022
Published online: 11 August 2022

References
1. Møller-Madsen B (2015) Arthrogryposis multiplex congenita—an update. J Child Orthop 9:425–426
2. Hall JG (2014) Arthrogryposis (multiple congenital contractures): diagnostic approach to etiology, classification, genetics, and general principles. Eur J Med Genet 57:464–472
3. Dahan-Oliel N, Cachecho S, Barnes D, Bedard T, Davison AM, Dreierich K, Donehoo M et al (2019) International multidisciplinary collaboration toward an annotated definition of arthrogryposis multiplex congenita. American journal of medical genetics. Part C Sem Med Genet 181:288–299
4. Xue S, Maluenda J, Marguet F, Shboul M, Quevarec L, Bonnard C, Ng AY et al (2017) Loss-of-function mutations in LG4, a secreted ligand involved in schwann cell myelination, are responsible for Arthrogryposis Multiplex Congenita. Am J Human Genet 100:659–665
5. Bamshad M, Van Heest AE, Pleasure D (2009) Arthropysiosis: a review and update. J Bone Joint Surg Am 91:40–46
6. Ambarger JS, Bocchini CA, Scott AF, Hamosh A (2019) OMIM.org: leveraging knowledge across phenotype–gene relationships. Nucleic Acids Res. 47(D1):D1038–D1043
7. Reinstein E, Drasinoiu V, Lotan R, Gal-Tanamy M, Bolcan Nachman I, Eyal E, Jaber L et al. (2018) Mutations in ERGIC1 cause Arthropysiosis multiplex congenita, neuropathic type. Clin Genet 93:160–163
8. Baumann M, S–GE, Krabchik B, Petersen B–S, Weber U, Schmidt WW, Zschock F, Muller T, Bitner RE, Janecke AR. (2017) Homozygous SYNE1 mutation causes congenital onset of muscular weakness with distal arthropysiosis: a genotype–phenotype correlation. Eur J Human Genet 25:262–266
9. Seidahmed MZ, A–KA, Alsaif HS, Miqdad A, Alabbad N, Alfiﬁ A, Abdelbasit OB, Alhussein K, Alsamadi A, Ibrahim N et al. (2020) Recessive mutations in SCYL2 cause a novel syndromic form of arthropysiosis in humans. Human Genet 139:513–519
10. Kimber E (2015) AMC: amyoplasia and distal arthropysiosis. J Child Orthop 9:427–432
11. Desai D, Stene D, Song T, Sadayappan S (2020) Distal arthropysiosis and lethal congenital contracture syndrome - an overview. Front Physiol 11:689
12. Stevenson DA, Swoboda KJ, Sanders RK, Bamshad M (2006) A new distal arthropysiosis syndrome characterized by planter ﬂexion contractures. Am J Med Genet A 140:2797–2801
13. Levine MS (1973) Congenital short tendon calciﬁc. Report of a family. Am J Dis Children 125:858–859
14. Zhou G, Soufan O, Ewald J, Hancock REW, Basu N, Xia J (2019) NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression proﬁling and meta-analysis. Nucleic Acids Res 47(W3):W234–W241
15. Orchard S, Kerrien S, Abbani S, Aranda B, Bhate J, Bidwell S, Bridge A et al. (2012) Protein interaction data curation: the International Molecular Exome (IMEx) consortium. Nat Methods 9:345–350
16. Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, Doncheva NM et al. (2015) ATLAS of genetics and cytogenetics in oncology and haematology. Nucleic Acids Res 43:D1038–D1043
17. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25:25–29
18. Thomas PD, Campbell MJ, Kejariwal A, Mi H, Karlak B, Daverne R, Diemer K et al. (2003) PANTHER: a library of protein families and subfamilies indexed by function. Genome Res 13:219–224
19. Joshi-Tope G, Gillespie M, Vastrik I, D’Eustachio P, Schmidt E, de Bono B, Jassal B et al. (2005) Reactome: a knowledgebase of biological pathways. Nucleic Acids Res. 33:D428–D432
20. Kanemitsa M, Sato Y, Kawashima M, Furumichi M, Tanabe M (2016) KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 43:D429–D437
21. Kimber E (2015) AMC: amyoplasia and distal arthropysiosis. J Child Orthop 9:427–432
22. Stevenson DA, Swoboda KJ, Sanders RK, Bamshad M (2006) A new distal arthropysiosis syndrome characterized by planter ﬂexion contractures. Am J Med Genet A 140:2797–2801
23. Levy MS (1973) Congenital short tendon calciﬁc. Report of a family. Am J Dis Children 125:858–859
24. Zhou G, Soufan O, Ewald J, Hancock REW, Basu N, Xia J (2019) NetworkAnalyst 3.0: a visual analytics platform for comprehensive gene expression proﬁling and meta-analysis. Nucleic Acids Res 47(W3):W234–W241
25. Orchard S, Kerrien S, Abbani S, Aranda B, Bhate J, Bidwell S, Bridge A et al. (2012) Protein interaction data curation: the International Molecular Exome (IMEx) consortium. Nat Methods 9:345–350
26. Szklarczyk D, Gable AL, Nastou KC, Lyon D, Kirsch R, Pyysalo S, Doncheva NM et al. (2015) ATLAS of genetics and cytogenetics in oncology and haematology. Nucleic Acids Res 43:D1038–D1043
27. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25:25–29
28. Thomas PD, Campbell MJ, Kejariwal A, Mi H, Karlak B, Daverne R, Diemer K et al. (2003) PANTHER: a library of protein families and subfamilies indexed by function. Genome Res 13:219–224
29. Joshi-Tope G, Gillespie M, Vastrik I, D’Eustachio P, Schmidt E, de Bono B, Jassal B et al. (2005) Reactome: a knowledgebase of biological pathways. Nucleic Acids Res. 33:D428–D432
30. Kanemitsa M, Sato Y, Kawashima M, Furumichi M, Tanabe M (2016) KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 43:D429–D437
prostate cancer adhesion and invasion via AKT activation. J Exp Clin Cancer Res 38:317
50. Jacq L, Garnier S, Dieudé P, Michou L, Pierlot C, Migliorini P, Balsa A et al (2007) The ITGAV rs3738919-C allele is associated with rheumatoid arthritis in the European Caucasian population: a family-based study. Arthritis Res Therapy 9:R63
51. Rappaport N, Nativ N, Stelzer G, Twik M, Guan-Golan Y, Stein TI, Bahir I et al (2013) MalaCards: an integrated compendium for diseases and their annotation. Database (Oxford):bat018
52. Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, Stein TI et al (2016) The GeneCards Suite: From gene data mining to disease genome sequence analyses. Curr Protoc Bioinformatics 54:1.30.31-31.30.33

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.